• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

13.62 +0.33 (+2.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins ↗
May 21, 2026
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass (CMPS) Q1 2026 Earnings Transcript ↗
May 13, 2026
Compass (CMPS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Q1 Earnings Call Highlights ↗
May 13, 2026
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for... 
Via MarketBeat
Topics Cannabis Earnings Government
CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗
January 07, 2026
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
 
Via Benzinga
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
April 27, 2026
Via MarketBeat
Topics Government
News headline image
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About ↗
April 23, 2026
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression. 
Via The Motley Fool
Topics Government
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
April 21, 2026
Via Chartmill
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
April 20, 2026
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
April 20, 2026
Via Chartmill
News headline image
This Psychedelic Biotech Stock Is Soaring After Trump Executive Order ↗
April 20, 2026
COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for... 
Via Benzinga
Topics Government
What's going on in today's session ↗
April 20, 2026
Via Chartmill
News headline image
Why Compass Pathways Stock Rocketed 40% Today ↗
April 20, 2026
Compass Pathways may be the first to benefit from an accelerated approval process. 
Via The Motley Fool
Topics Government
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
April 20, 2026
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
April 20, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 20, 2026
Via Chartmill
News headline image
The Psychedelic Revolution in Mental Healthcare ↗
April 17, 2026
Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and... 
Via The Motley Fool
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
March 26, 2026
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
February 20, 2026
Via MarketBeat
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
February 19, 2026
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗
February 18, 2026
The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter. 
Via Stocktwits
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
February 17, 2026
Via Chartmill
News headline image
Why Did Compass Pathways Stock Rocket Higher Today? ↗
February 17, 2026
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval. 
Via The Motley Fool
Tuesday's session: gap up and gap down stocks ↗
February 17, 2026
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
February 17, 2026
Via Chartmill
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
February 17, 2026
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
February 17, 2026
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
December 24, 2025
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
November 04, 2025
 
Via Benzinga
News headline image
Compass (CMPS) Q2 Loss Improves 27% ↗
August 01, 2025
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap